Advances in human microbiome and prostate cancer research DOI Creative Commons
Xin Pei, Lei Liu, Yuping Han

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 14, 2025

Prostate cancer (PCa) is the second most common malignant tumor in men worldwide, and its metastatic heterogeneous nature makes it significantly more difficult to treat. Recent studies have revealed critical role of microbiota PCa occurrence, progression, treatment. Accumulating evidence from 16S rRNA metagenomic sequencing suggests presence specific prostate tissues macrogenomics techniques: cancerous are enriched with pro-inflammatory genera (e.g., Fusobacterium , Propionibacterium acnes ), whereas commensal bacteria Pseudomonas ) paracancerous tissues. The drive progression through activation NF-κB/STAT3 pathway induce chronic inflammation, modulation immune microenvironment Treg/Th17 imbalance M2-type macrophage polarization), metabolite LPS, short-chain fatty acids)–mediated hormonal epigenetic regulation. In terms clinical translation, urinary characterization combined metabolomics analysis may enhance diagnostic specificity, while gut flora probiotic interventions or fecal transplants) improve resistance androgen deprivation therapy. Current challenges include accuracy low-biomass samples, limitations causal mechanism validation models, large cohort heterogeneity. future, will be necessary integrate multi-omics technologies explore bidirectional regulation “gut-prostate axis” develop personalized therapeutic strategies targeting microorganisms. this paper, we systematically review interactions between their potentials provide a theoretical basis for precision diagnosis

Language: Английский

Advances in human microbiome and prostate cancer research DOI Creative Commons
Xin Pei, Lei Liu, Yuping Han

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 14, 2025

Prostate cancer (PCa) is the second most common malignant tumor in men worldwide, and its metastatic heterogeneous nature makes it significantly more difficult to treat. Recent studies have revealed critical role of microbiota PCa occurrence, progression, treatment. Accumulating evidence from 16S rRNA metagenomic sequencing suggests presence specific prostate tissues macrogenomics techniques: cancerous are enriched with pro-inflammatory genera (e.g., Fusobacterium , Propionibacterium acnes ), whereas commensal bacteria Pseudomonas ) paracancerous tissues. The drive progression through activation NF-κB/STAT3 pathway induce chronic inflammation, modulation immune microenvironment Treg/Th17 imbalance M2-type macrophage polarization), metabolite LPS, short-chain fatty acids)–mediated hormonal epigenetic regulation. In terms clinical translation, urinary characterization combined metabolomics analysis may enhance diagnostic specificity, while gut flora probiotic interventions or fecal transplants) improve resistance androgen deprivation therapy. Current challenges include accuracy low-biomass samples, limitations causal mechanism validation models, large cohort heterogeneity. future, will be necessary integrate multi-omics technologies explore bidirectional regulation “gut-prostate axis” develop personalized therapeutic strategies targeting microorganisms. this paper, we systematically review interactions between their potentials provide a theoretical basis for precision diagnosis

Language: Английский

Citations

0